trending Market Intelligence /marketintelligence/en/news-insights/trending/CTfVmjoFw1bXFoai3G__ug2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

US court denies billionaire Soon-Shiong's motion to dismiss Sorrento litigation

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


US court denies billionaire Soon-Shiong's motion to dismiss Sorrento litigation

A Los Angeles Superior Court judge denied NantPharma LLC and billionaire Patrick Soon-Shiong's motion to stay or dismiss a fraud case filed by biotechnology company Sorrento Therapeutics Inc.

The Los Angeles Superior Court also granted Sorrento's motions to compel Soon-Shiong company NantCell's counterclaims to arbitration, the company said in a news release.

Soon-Shiong, chairman and CEO of NantWorks LLC, is the inventor of breast cancer drug Abraxane. NantPharma, a unit of NantWorks, bought experimental cancer drug Cynviloq from Sorrento in 2015 as part of a deal involving $90 million cash plus $1.2 billion in potential milestone payments.

In April, San Diego-based Sorrento company sued Soon-Shiong, who is also the owner of the Los Angeles Times, and his companies for alleged fraud and breach of contract by buying Cynviloq and halting its market development. Sorrento claimed the parties orchestrated to keep Cynviloq off the market to preserve Soon-Shiong's personal financial interest in another competing drug.